Immune checkpoint inhibitor-induced hemophagocytic lymphohistiocytosis in lung cancer: a case series
Abdul Wali Khan , Simran Chandra , Himil Mahadevia , Janakiraman Subramanian , Ben Ponvilawan , Dhruv Bansal
Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) : 1002347
Immune checkpoint inhibitors (ICIs) are established treatments for various malignancies, including lung, kidney, and colorectal cancers. However, their broad use has led to an increase in immune-related adverse events (irAEs), with thyroiditis, colitis, and pneumonitis being the most common. Hemophagocytic lymphohistiocytosis (HLH) is a rare but severe irAE characterized by excessive immune activation, leading to systemic inflammation and multi-organ dysfunction. We present three cases of ICI-induced HLH in patients with lung cancer who were treated with ICIs. All patients showed elevated inflammatory markers and responded to high-dose corticosteroids without the addition of etoposide. These cases underscore the importance of early recognition and treatment of HLH in patients receiving ICIs to mitigate morbidity and mortality. Large-scale studies are needed to establish standardized guidelines for diagnosing and managing ICI-induced HLH.
immune checkpoint inhibitors / HLH / lung cancer
| [1] |
Small Cell Lung Cancer [Internet]. National Comprehensive Cancer Network; c2025 [cited 2025 Sep 2]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf |
| [2] |
Colon Cancer [Internet]. National Comprehensive Cancer Network; c2025 [cited 2025 Sep 2]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf |
| [3] |
Kidney Cancer [Internet]. National Comprehensive Cancer Network; c2025 [cited 2025 Sep 2]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf |
| [4] |
|
| [5] |
Henter JI. Hemophagocytic Lymphohistiocytosis. N Engl J Med. 2025; 392: 584-98. |
| [6] |
|
| [7] |
|
| [8] |
Mizuta H, Nakano E, Takahashi A, Koyama T, Namikawa K, |
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, |
| [14] |
|
| [15] |
|
/
| 〈 |
|
〉 |